{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:21:19Z","timestamp":1787008879519,"version":"build-2736575974"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"3","funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50DA054072"],"award-info":[{"award-number":["P50DA054072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U2CDA057717"],"award-info":[{"award-number":["U2CDA057717"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Offering patients medications for opioid use disorder (MOUD) is the standard of care for opioid use disorder (OUD), but an estimated 75%\u201390% of people with OUD who could benefit from MOUD do not receive medication. Payment policy, defined as public and private payers\u2019 approaches to covering and reimbursing providers for MOUD, is 1 contributor to this treatment gap. We conducted a policy analysis and qualitative interviews (n = 21) and surveys (n = 31) with US MOUD payment policy experts to characterize MOUD insurance coverage across major categories of US insurers and identify opportunities for reform and innovation. Traditional Medicare, Medicare Advantage, and Medicaid all provide coverage for at least 1 formulation of buprenorphine, naltrexone, and methadone for OUD. Private insurance coverage varies by carrier and by plan, with methadone most likely to be excluded. The experts interviewed cautioned against rigid reimbursement models that force patients into one-size-fits-all care and endorsed future development and adoption of value-based MOUD payment models. More than 70% of experts surveyed reported that Medicare, Medicaid, and private insurers should increase payment for office- and opioid treatment program\u2013based MOUD. Validation of MOUD performance metrics is needed to support future value-based initiatives.<\/jats:p>","DOI":"10.1093\/haschl\/qxae024","type":"journal-article","created":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T17:05:53Z","timestamp":1708880753000},"source":"Crossref","is-referenced-by-count":13,"title":["US payment policy for medications to treat opioid use disorder: landscape and opportunities"],"prefix":"10.1093","volume":"2","author":[{"given":"Emma E","family":"McGinty","sequence":"first","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medical College , New York, NY 10065 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-1809","authenticated-orcid":false,"given":"Sarah A","family":"White","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0231-1158","authenticated-orcid":false,"given":"Nicole R","family":"Palmer","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College , New York, NY 10065 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0294-2419","authenticated-orcid":false,"given":"C Hendricks","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University , Chicago, IL 60611 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan K","family":"Saloner","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health , Baltimore, MD 21205 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"2024032009083841000_qxae024-B1","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences Engineering and Medicine","year":"2019"},{"key":"2024032009083841000_qxae024-B2","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"2024032009083841000_qxae024-B3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08897077.2021.1986768","article-title":"COVID-19-related policy changes for methadone take-home dosing: a multistate survey of opioid treatment program leadership","volume":"43","author":"Levander","year":"2022","journal-title":"Subst Abus"},{"key":"2024032009083841000_qxae024-B4","doi-asserted-by":"crossref","first-page":"103786","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the US? A yearly assessment from 2010 to 2019","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"3","key":"2024032009083841000_qxae024-B5","doi-asserted-by":"crossref","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10118","key":"2024032009083841000_qxae024-B6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"2024032009083841000_qxae024-B7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"14","key":"2024032009083841000_qxae024-B8","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","article-title":"Intervention stigma toward medications for opioid use disorder: a systematic review","volume":"56","author":"Madden","year":"2021","journal-title":"Subst Use Misuse"},{"issue":"7","key":"2024032009083841000_qxae024-B9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.7326\/M19-2403","article-title":"Growth and distribution of buprenorphine-waivered providers in the United States, 2007\u20132017","volume":"172","author":"McBain","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024032009083841000_qxae024-B10","first-page":"10.31478\/202004b","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system","volume":"2020","author":"Madras","year":"2020","journal-title":"NAM Perspect"},{"issue":"8","key":"2024032009083841000_qxae024-B11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1377\/hlthaff.2011.0480","article-title":"The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act","volume":"30","author":"Buck","year":"2011","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"2024032009083841000_qxae024-B12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.37765\/ajmc.2022.89250","article-title":"The impact of HDHPs on service use and spending for substance use disorders","volume":"28","author":"Eisenberg","year":"2022","journal-title":"Am J Managed Care"},{"key":"2024032009083841000_qxae024-B13","author":"Centers for Disease Control and Prevention"},{"key":"2024032009083841000_qxae024-B14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4324\/9780367824471-37","volume-title":"Qualitative Content Analysis. the Routledge Handbook of Research Methods in Applied Linguistics","author":"Selvi","year":"2019"},{"issue":"1","key":"2024032009083841000_qxae024-B15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10488-010-0314-z","article-title":"Mixed method designs in implementation research","volume":"38","author":"Palinkas","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"2024032009083841000_qxae024-B16","author":"Musumeci"},{"key":"2024032009083841000_qxae024-B17","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B18","article-title":"New methadone treatment regulations should be complemented by payment and financing reform","author":"Bowser","year":"2023","journal-title":"Health Affairs Forefront"},{"issue":"1","key":"2024032009083841000_qxae024-B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13722-021-00253-7","article-title":"Financial sustainability of payment models for office-based opioid treatment in outpatient clinics","volume":"16","author":"Hodgkin","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"7","key":"2024032009083841000_qxae024-B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.37765\/ajmc.2020.43747","article-title":"Innovative payment to scale up access to medications for opioid use disorder","volume":"26","author":"Polsky","year":"2020","journal-title":"Am J Manag Care"},{"issue":"4","key":"2024032009083841000_qxae024-B21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ADM.0000000000000310","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J Addict Med"},{"key":"2024032009083841000_qxae024-B22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jsat.2019.07.013","article-title":"Implementation of the hub and spoke model for opioid use disorders in California: rationale, design and anticipated impact","volume":"108","author":"Miele","year":"2020","journal-title":"J Subst Abuse Treat"},{"key":"2024032009083841000_qxae024-B23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2017.10.001","article-title":"Experiences of three states implementing the Medicaid health home model to address opioid use disorder\u2014case studies in Maryland, Rhode Island, and Vermont","volume":"83","author":"Clemans-Cope","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2024032009083841000_qxae024-B24","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B25","volume-title":"Moving Toward Value-Based Payment for Medicaid Behavioral Health Services","author":"Soper","year":"2017"},{"issue":"2","key":"2024032009083841000_qxae024-B26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15288\/jsad.2021.82.214","article-title":"Prior authorization for opioid use disorder versus pain medications: lessons learned for parity enforcement","volume":"82","author":"Mark","year":"2021","journal-title":"J Stud Alcohol Drugs"},{"issue":"5","key":"2024032009083841000_qxae024-B27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1377\/hlthaff.2022.01513","article-title":"Buprenorphine treatment for opioid use disorder: comparison of insurance restrictions, 2017\u201321: study examines insurance restrictions on buprenorphine treatment for opioid use disorder","volume":"42","author":"Andraka-Christou","year":"2023","journal-title":"Health Aff (Millwood)"},{"key":"2024032009083841000_qxae024-B28","author":"Substance Abuse and Mental Health Services Administration"},{"issue":"1","key":"2024032009083841000_qxae024-B29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/07853890.2023.2171107","article-title":"Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019","volume":"55","author":"Andraka-Christou","year":"2023","journal-title":"Ann Med"},{"key":"2024032009083841000_qxae024-B30","author":"Kaiser Family Foundation"},{"key":"2024032009083841000_qxae024-B31"},{"key":"2024032009083841000_qxae024-B32","doi-asserted-by":"crossref","first-page":"108540","DOI":"10.1016\/j.jsat.2021.108540","article-title":"Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder","volume":"133","author":"Morgan","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2024032009083841000_qxae024-B33"},{"key":"2024032009083841000_qxae024-B34"},{"issue":"8","key":"2024032009083841000_qxae024-B35","doi-asserted-by":"crossref","first-page":"e232502","DOI":"10.1001\/jamahealthforum.2023.2502","article-title":"Changes in Medicaid fee-for-service benefit design for substance use disorder treatment during the opioid crisis, 2014 to 2021","volume":"4","author":"Shoulders","year":"2023","journal-title":"JAMA Health Forum"},{"key":"2024032009083841000_qxae024-B36","doi-asserted-by":"crossref","first-page":"108784","DOI":"10.1016\/j.drugalcdep.2021.108784","article-title":"Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?","volume":"225","author":"Dunphy","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"2024032009083841000_qxae024-B37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MLR.0000000000001689","article-title":"Variation in initiation, engagement, and retention on medications for opioid use disorder based on health insurance plan design","volume":"60","author":"Morgan","year":"2022","journal-title":"Med Care"},{"issue":"1","key":"2024032009083841000_qxae024-B38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13011-022-00478-y","article-title":"Medicaid professional fees for treatment of opioid use disorder varied widely across states and were substantially below fees paid by Medicare in 2021","volume":"17","author":"Clemans-Cope","year":"2022","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"2024032009083841000_qxae024-B39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ps.201900373","article-title":"Private coverage of methadone in outpatient treatment programs","volume":"71","author":"Polsky","year":"2020","journal-title":"Psychiatr Serv"},{"key":"2024032009083841000_qxae024-B40","author":"Hellmann"},{"key":"2024032009083841000_qxae024-B41","author":"Freed"},{"key":"2024032009083841000_qxae024-B42","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B43","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B44","volume-title":"The Effect of Increased Cost-Sharing in Medicaid: A Summary of Research Findings","author":"Ku","year":"2005"},{"key":"2024032009083841000_qxae024-B45","author":"Medicaid and CHIP Payment and Access Commission (MACPAC)"},{"key":"2024032009083841000_qxae024-B46","author":"Guth"},{"issue":"11","key":"2024032009083841000_qxae024-B47","doi-asserted-by":"crossref","first-page":"e224001","DOI":"10.1001\/jamahealthforum.2022.4001","article-title":"Coverage and prior authorization policies for medications for opioid use disorder in Medicaid managed care","volume":"3","author":"Abraham","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"7","key":"2024032009083841000_qxae024-B48","doi-asserted-by":"crossref","first-page":"e221821","DOI":"10.1001\/jamahealthforum.2022.1821","article-title":"Trends in buprenorphine coverage and prior authorization requirements in US commercial formularies, 2017-2021","volume":"3","author":"Nguyen","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"9","key":"2024032009083841000_qxae024-B49","doi-asserted-by":"crossref","first-page":"e2329583","DOI":"10.1001\/jamanetworkopen.2023.29583","article-title":"Economic evaluation of extended-release buprenorphine for persons with opioid use disorder","volume":"6","author":"Flam-Ross","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2024032009083841000_qxae024-B50","author":"Hinton"},{"key":"2024032009083841000_qxae024-B51","author":"Gifford"},{"key":"2024032009083841000_qxae024-B52","author":"US Food and Drug Administration"},{"key":"2024032009083841000_qxae024-B53","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B54","author":"Agency for Healthcare Research and Quality"},{"issue":"6","key":"2024032009083841000_qxae024-B55","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1176\/appi.ajp.20220456","article-title":"Performance measurement for opioid use disorder medication treatment and care retention","volume":"180","author":"Williams","year":"2023","journal-title":"Am J Psychiatry"},{"key":"2024032009083841000_qxae024-B56","doi-asserted-by":"crossref","first-page":"108824","DOI":"10.1016\/j.jsat.2022.108824","article-title":"Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder","volume":"140","author":"Dowd","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2024032009083841000_qxae024-B57","author":"Mark"},{"issue":"1","key":"2024032009083841000_qxae024-B58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1001\/jamapsychiatry.2022.3538","article-title":"Value-based payment and behavioral health","volume":"80","author":"Pincus","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"2024032009083841000_qxae024-B59","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/add.14248","article-title":"Effects of a prior authorization policy for extended-release\/long-acting opioids on utilization and outcomes in a state Medicaid program","volume":"113","author":"Keast","year":"2018","journal-title":"Addiction"},{"key":"2024032009083841000_qxae024-B60","author":"Assistant Secretary for Planning and Evaluation Office of Health Policy"},{"key":"2024032009083841000_qxae024-B61","author":"Weber"},{"key":"2024032009083841000_qxae024-B62","first-page":"e220189","volume-title":"The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid\u2014Building an Evidence Base","author":"Allen","year":"2022"},{"key":"2024032009083841000_qxae024-B63","first-page":"e221757","volume-title":"Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs","author":"Keshwani","year":"2022"},{"issue":"4","key":"2024032009083841000_qxae024-B64","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/10775587231167514","article-title":"State policy and the breadth of buprenorphine-prescriber networks in Medicaid managed care","volume":"80","author":"Meiselbach","year":"2023","journal-title":"Med Care Res Rev"},{"key":"2024032009083841000_qxae024-B65","author":"American College of Emergency Physicians"},{"key":"2024032009083841000_qxae024-B66","author":"Huskamp"},{"key":"2024032009083841000_qxae024-B67","author":"American Hospital Association"},{"key":"2024032009083841000_qxae024-B68","author":"American Medical Association. Docket No. DEA-948"},{"issue":"3","key":"2024032009083841000_qxae024-B69","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1468-0009.12584","article-title":"How emerging telehealth models challenge policymaking","volume":"100","author":"Tang","year":"2022","journal-title":"Milbank Q"},{"issue":"5","key":"2024032009083841000_qxae024-B70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/ADM.0000000000000950","article-title":"Office-based methadone prescribing for opioid use disorder: the Canadian model","volume":"16","author":"Kleinman","year":"2022","journal-title":"J Addict Med"},{"issue":"10","key":"2024032009083841000_qxae024-B71","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.283.10.1343","article-title":"Provision of methadone treatment in primary care medical practices: review of the Scottish experience and implications for US policy","volume":"283","author":"Weinrich","year":"2000","journal-title":"JAMA"},{"issue":"11","key":"2024032009083841000_qxae024-B72","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamapsychiatry.2020.1511","article-title":"Methadone for opioid use disorder\u2014decades of effectiveness but still miles away in the US","volume":"77","author":"Joudrey","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2024032009083841000_qxae024-B73","author":"Cubanski"},{"key":"2024032009083841000_qxae024-B74","author":"Freed"},{"key":"2024032009083841000_qxae024-B75","author":"Hinton"},{"key":"2024032009083841000_qxae024-B76","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B77","author":"Medicaid and CHIP Payment and Access Commission (MACPAC)"},{"key":"2024032009083841000_qxae024-B78","author":"Centers for Medicare and Medicaid Services"},{"key":"2024032009083841000_qxae024-B79","author":"Corlette"},{"key":"2024032009083841000_qxae024-B80","author":"Wang"},{"key":"2024032009083841000_qxae024-B81","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2024032009083841000_qxae024-B82","author":"Substance Abuse and Mental Health Services Administration"}],"container-title":["Health Affairs Scholar"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/advance-article-pdf\/doi\/10.1093\/haschl\/qxae024\/56773325\/qxae024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/3\/qxae024\/57023504\/qxae024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article-pdf\/2\/3\/qxae024\/57023504\/qxae024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T08:04:11Z","timestamp":1710921851000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/healthaffairsscholar\/article\/doi\/10.1093\/haschl\/qxae024\/7615100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":82,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/haschl\/qxae024","relation":{},"ISSN":["2976-5390"],"issn-type":[{"value":"2976-5390","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,27]]},"article-number":"qxae024"}}